

POLAND

Recent and planned developments in pharmaceutical policies 2016

Special topic: Out-of pocket payments

D E V E L O P M E N T S	CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
	<p>- No changes</p>	<p>Changes implemented:</p> <ul style="list-style-type: none"> - from 1 September 2016 polish pensioners aged 75 and over are entitled to a range of free medicines from a list issued by the Ministry of Health (MoH). <p>Planned changes (not implemented):</p> <ul style="list-style-type: none"> - It is planned to implement the reimbursement approval process (that is now performed by the MoH) also for a broader scope of medical devices such as lens or adult diapers. Thereby medical devices will be subjected to assessment of polish HTA agency and to price negotiation with the Economic Commission affiliated with the MoH Health. - Similar changes considering reimbursement approval process, assessment of polish HTA agency, and price negotiation will apply to drugs for HIV, AIDS treatments as well as to drugs used in haemophilia treatment
OTHER CHANGES		
<p>The reimbursement approval process that is performed by the polish MoH requires pharmaceutical companies to complete a reimbursement submission form. From 1 January 2017 entire process including submitting applications, assessment of polish HTA agency, price negotiation with the Economic Commission will be performed on-line via new IT system called SOLR (System of reimbursement list service).</p>		
S P E C I A L T O P I C	OUT-OF POCKET PAYMENTS	
	<p>Out-patient In Poland drugs are qualified to one of the following patient contribution: free of charge, flat payments [3,20 zł (ca. 0,73 Euro) per unit containing 30 DDDs], 50%, 30%. Patient's contribution level refers to the financing limit set for the given limit group. The patient pays also the difference between the retail price and the financing limit. Additionally, from 1 September 2016 polish pensioners aged 75 and over are entitled to a range of free medicines from a list issued by the Ministry of Health.</p> <p>While Poland's retail pharmaceutical market in 2015 reach a value of EUR 6,76 billion, total expenditures for reimbursed medicines amounted ca. EUR 2,6 billion. Average patients payment was 31,5 % of a retail price.</p> <p>OTC medicines that are not prescribed are to be fully paid out-of pocket by the patient</p> <p>In-patient In the in-patient sector all medicines are free of charge for patients (including those drugs which are not included in the list of reimbursed drugs).</p>	